文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

仑伐替尼联合免疫检查点抑制剂治疗晚期肝细胞癌的安全性和有效性。

The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.

机构信息

Hospital of Qingdao University, Qingdao, China.

Hospital of Qingdao University, Qingdao, China.

出版信息

Biomed Pharmacother. 2020 Dec;132:110797. doi: 10.1016/j.biopha.2020.110797. Epub 2020 Oct 14.

DOI:10.1016/j.biopha.2020.110797
PMID:33068935
Abstract

China has one of the highest incidence rates of hepatocellular carcinoma (HCC) in the world. As most patients are diagnosed with advanced or unretractable HCC, systematic therapy is still the main treatment method for HCC. Currently, tyrosine kinase inhibitors (TKIs) and Immune checkpoint inhibitors (ICIs) are both the chief systematic therapy. And some studies have shown that the combination of TKIs and ICIs is more effective than monotherapy. The purpose of this review is to outline the rationale for the combination between lenvatinib and anti-PD-1(programmed cell death 1) and clinical trials to support this "golden combination". We also discuss the commonly treatment-emergent adverse events (AEs) and solutions for the patients with HCC who received the combination between lenvatinib and anti-PD-1 antibodies. Finally, we focus on the novel approaches, future perspectives and potential challenges about the combination of TKIs and ICIs.

摘要

中国是世界上肝细胞癌 (HCC) 发病率最高的国家之一。由于大多数患者被诊断为晚期或不可切除的 HCC，系统治疗仍然是 HCC 的主要治疗方法。目前，酪氨酸激酶抑制剂 (TKI) 和免疫检查点抑制剂 (ICI) 都是主要的系统治疗方法。一些研究表明，TKI 和 ICI 的联合治疗比单药治疗更有效。本综述的目的是概述仑伐替尼联合抗 PD-1（程序性细胞死亡 1）的理论基础，并提供支持这种“黄金组合”的临床试验。我们还讨论了接受仑伐替尼联合抗 PD-1 抗体治疗的 HCC 患者常见的治疗相关不良事件 (AE) 及其解决方案。最后，我们关注 TKI 和 ICI 联合治疗的新方法、未来前景和潜在挑战。

相似文献

[1]
The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.

Biomed Pharmacother. 2020-12

[2]
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.

Cancer Med. 2024-5

[3]
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.

World J Surg Oncol. 2024-5-6

[4]
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.

Expert Rev Clin Pharmacol. 2021-11

[5]
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.

Biochim Biophys Acta Rev Cancer. 2020-7-10

[6]
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.

BMC Cancer. 2021-10-19

[7]
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.

Cancer Sci. 2018-11-16

[8]
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.

Hepatology. 2021-11

[9]
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Hepatology. 2021-11

[10]
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.

Immunotherapy. 2021-12

引用本文的文献

[1]
Peptide-Drug Conjugates: A New Hope for Cancer.

J Pept Sci. 2025-8

[2]
Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study.

Sci Rep. 2025-7-1

[3]
Pretreatment Multi-sequence Contrast-Enhanced MRI to Predict Response to Immunotherapy in Unresectable Hepatocellular Carcinoma Using Transformer: A Multicenter Study.

J Cancer. 2025-6-12

[4]
Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC.

Front Oncol. 2025-4-28

[5]
Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma.

Clin Exp Med. 2025-3-19

[6]
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib.

Sci Rep. 2025-1-9

[7]
Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study.

J Hepatocell Carcinoma. 2024-9-28

[8]
Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis.

Immunotargets Ther. 2024-6-17

[9]
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.

World J Gastroenterol. 2024-2-28

[10]
Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.

Front Oncol. 2024-2-16

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索